Citation Impact
Citing Papers
Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming
2016
Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice
2017
Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
2015
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
2016 Standout
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
2017
ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40–Mediated Tumor Rejection
2016 StandoutNobel
An engineered 4-1BBL fusion protein with “activity on demand”
2020
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin
2013 StandoutNobel
Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis
2010
The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
2014
TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies
2019
A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
2017
Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies
2012
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect
2012
Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice
2023 StandoutNobel
Target-conditioned diffusion generates potent TNFR superfamily antagonists and agonists
2024 StandoutScienceNobel
Targeting the tumor vasculature to enhance T cell activity
2015
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
Regulatory T-cell directed therapies in liver diseases
2013 StandoutNobel
Delivering safer immunotherapies for cancer
2017
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
2017
Physical nanoscale conduit-mediated communication between tumour cells and the endothelium modulates endothelial phenotype
2015
Clearance of apoptotic neutrophils and resolution of inflammation
2016
Engineering precision nanoparticles for drug delivery
2020 Standout
Dendritic cells in cancer immunology and immunotherapy
2019 Standout
Tregopathies: Monogenic diseases resulting in regulatory T-cell deficiency
2018
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
Immune Response Regulation in the Tumor Microenvironment by Hypoxia
2015
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Extracellular Vesicle RNA: A Universal Mediator of Microbial Communication?
2018 StandoutNobel
Transforming Growth Factor-β Signaling in Immunity and Cancer
2019 Standout
The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease
2017 Standout
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
Complement: coming full circle
2009
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Type I interferons in infectious disease
2015 Standout
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy
2013
Evaluating the Cellular Targets of Anti-4-1BB Agonist Antibody during Immunotherapy of a Pre-Established Tumor in Mice
2010
Immunogenic cell death in cancer and infectious disease
2016 Standout
The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?
2009
Complement: a key system for immune surveillance and homeostasis
2010 Standout
Fingolimod modulates T cell phenotype and regulatory T cell plasticity in vivo
2018
Delivery technologies for cancer immunotherapy
2019 Standout
Evolving synergistic combinations of targeted immunotherapies to combat cancer
2015
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
2015
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
Molecular Determinants of Regulatory T Cell Development: The Essential Roles of Epigenetic Changes
2013 StandoutNobel
Immunopathology of multiple sclerosis
2015 Standout
Identification of T helper type 1–like, Foxp3+ regulatory T cells in human autoimmune disease
2011
Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
2010
Immune checkpoint modulation: Rational design of combination strategies
2015
The immunology of stroke: from mechanisms to translation
2011 Standout
Molecular mechanisms of T cell co-stimulation and co-inhibition
2013 Standout
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
2016 Standout
Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy
2017
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Macrophages as regulators of tumour immunity and immunotherapy
2019 Standout
The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience
2014
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target
2020
Immunogenic cell stress and death
2022
PGE2-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment
2022 StandoutNobel
Clinical targeting of the TNF and TNFR superfamilies
2013
Lymphatics in Neurological Disorders: A Neuro-Lympho-Vascular Component of Multiple Sclerosis and Alzheimer’s Disease?
2016
Regulatory T Cell-Specific Epigenomic Region Variants Are a Key Determinant of Susceptibility to Common Autoimmune Diseases
2020 StandoutNobel
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS
2015
Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
2014
Interferons α and β in cancer: therapeutic opportunities from new insights
2019
Quantitative Super-Resolution Microscopy of the Mammalian Glycocalyx
2019 StandoutNobel
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons
2017 StandoutNobel
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
2017 Standout
Regulatory T Cells and Human Disease
2020 StandoutNobel
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
2022 StandoutNobel
In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism
2023 StandoutNobel
Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer
2020
Intratumoral Immunization: A New Paradigm for Cancer Therapy
2014
Multiple Sclerosis
2018 Standout
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
2019
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens
2015
Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment
2018
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment
2022
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia
2015
Cutting Edge: Engineering Active IKKβ in T Cells Drives Tumor Rejection
2016
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18
2016
Works of Iván Martínez‐Forero being referenced
Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model
2013
Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
2015
Paradigms on Immunotherapy Combinations with Chemotherapy
2021
Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes
2011
Intratumoral injection of interferon‐α and systemic delivery of agonist anti‐CD137 monoclonal antibodies synergize for immunotherapy
2010
CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs
2018
Synergistic effects of CTLA‐4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo
2010
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ
2010
Dendritic Cells Take up and Present Antigens from Viable and Apoptotic Polymorphonuclear Leukocytes
2011
Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN‐α
2010
IL‐10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis
2008
CD137 on inflamed lymphatic endothelial cells enhances CCL21‐guided migration of dendritic cells
2012
T Cell Costimulation with Anti-CD137 Monoclonal Antibodies Is Mediated by K63–Polyubiquitin-Dependent Signals from Endosomes
2013
Clinical Development of Combination Strategies in Immunotherapy: are We Ready for More Than One Investigational Product in an Early Clinical Trial?
2009
The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy
2012
Lysine 63 Polyubiquitination in Immunotherapy and in Cancer-promoting Inflammation
2009
Therapeutic activity of a combination of immunostimulatory monoclonal antibodies (anti-B7-H1, CD137 and OX40) on a c-myc-driven spontaneous transgenic model of hepatocellular carcinoma
2013